| Email Article | Print |
Signaling protein helps limit damage in heart attack, Jefferson scientists show
March 24, 2008(PHILADELPHIA) Scientists at the Center for Translational Medicine at Thomas Jefferson University in Philadelphia have shown that a specific signaling protein is crucial to protecting the heart and helping it to adapt during a heart attack.
The protein Gi is known to have increased activity in the failing heart, but researchers have never been sure if it was helping the heart adapt to damage or if it was actually causing more heart cells to die. The Jefferson team, led by Walter Koch, Ph.D., W.W. Smith Professor of Medicine and director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College, experimentally blocked the protein in the hearts of genetically engineered mice experiencing heart attacks. They found that the animals had greater heart damage than did similar mice with a working protein. The team reports its findings March 18, 2008, in the journal Circulation.
Gi is important in intracellular signaling, akin to a molecular switch, Dr. Koch notes. It's not a new drug target, he explains, but the activation of some receptors (such as beta-2 adrenergic receptors) that also turn on Gi could be targets.
Developing a "class-specific Gi inhibitor," Dr. Koch explains, is an important step to understanding Gi's role and behavior. "We don't have to worry about what receptor we are blocking; we're blocking a receptor that couples with Gi. We never had the tools before to tell if Gi activation was good or bad. We think that we can now begin to test the role of Gi in cardiac injury."
In the work, Dr. Koch's group developed a transgenic mouse with a "functional knockout" of the Gi gene, meaning that it lacked a working gene. The scientists then simulated a heart attack, catheterization and reperfusion by tieing off a coronary artery for 30 minutes and subsequently reestablishing the blood flow, causing an inflammatory response and tissue damage.
"It appears that in this setting, Gi is an important protective mechanism," Dr. Koch says. "The heart wants to activate Gi and attempt to protect cardiac myocytes from dying. We found that in this acute setting, heart attacks are bigger when Gi is blocked." As a result, the heart can't pump as well.
They would like to find out Gi's role in chronic heart failure, where there is much less cell death occurring, and Gi levels remain high. In the chronic phase, Dr. Koch points out, Gi activity could be "maladaptive." They plan to test the idea in chronic heart failure animal models.
Thomas Jefferson University
Developing a "class-specific Gi inhibitor," Dr. Koch explains, is an important step to understanding Gi's role and behavior. "We don't have to worry about what receptor we are blocking; we're blocking a receptor that couples with Gi. We never had the tools before to tell if Gi activation was good or bad. We think that we can now begin to test the role of Gi in cardiac injury."
In the work, Dr. Koch's group developed a transgenic mouse with a "functional knockout" of the Gi gene, meaning that it lacked a working gene. The scientists then simulated a heart attack, catheterization and reperfusion by tieing off a coronary artery for 30 minutes and subsequently reestablishing the blood flow, causing an inflammatory response and tissue damage.
"It appears that in this setting, Gi is an important protective mechanism," Dr. Koch says. "The heart wants to activate Gi and attempt to protect cardiac myocytes from dying. We found that in this acute setting, heart attacks are bigger when Gi is blocked." As a result, the heart can't pump as well.
They would like to find out Gi's role in chronic heart failure, where there is much less cell death occurring, and Gi levels remain high. In the chronic phase, Dr. Koch points out, Gi activity could be "maladaptive." They plan to test the idea in chronic heart failure animal models.
Thomas Jefferson University
Signaling Protein News and Current Signaling Protein Events RSSBlocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
Researchers at Jefferson's Kimmel Cancer Center in Philadelphia have shown that they can effectively kill prostate cancer cells in both the laboratory and in experimental animal models by blocking a signaling protein that is key to the cancer's growth.
Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy.
Ireland Cancer Center researchers advance stem cell gene therapy
Ireland Cancer Center of University Hospitals Case Medical Center researchers have recently made great strides in stem cell gene therapy research by transferring a new gene to cancer patients, via their own stem cells, with the ultimate goal of being able to use stronger chemotherapy treatment with less severe side effects.
Researchers led by Penn vet uncover the delicate protein balance behind the immune system response
A team of researchers from the University of Pennsylvania School of Veterinary Medicine has identified the protein interactions involved in the immune system process that fights infection yet, in certain inflammatory diseases, runs amok and attacks friendly tissue.
Emory researchers identify signaling protein for multiple myeloma
Researchers at Emory University's Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival.
Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
Angiogenesis inhibitors that block a tumor's development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy.
Marijuana component opens the door for virus that causes Kaposi's sarcoma
The major active component of marijuana could enhance the ability of the virus that causes Kaposi's sarcoma to infect cells and multiply.
BCM, Rice make major advance in structural biology
Scientists from Baylor College of Medicine (BCM) and Rice University have discovered a new way to analyze the moving parts of large proteins - a breakthrough that will make it easier for structural biologists to classify and scrutinize the active sites of proteins implicated in cancer and other diseases.
Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses
Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.
How genetic malfunction causes a form of retardation
Researchers have discovered that the genetic malfunction that causes a form of mental retardation called Noonan Syndrome (NS) produces an imbalance in the genesis of two types of cells in the developing embryonic brain.
More Signaling Protein News Articles
| © 2008 BrightSurf.com |